Autopsy report · NCT05295589

Comparing Standard of Care Chemotherapy Treatment to the Combination of Copanlisib and Olaparib for Recurrent Platinum Resistant Ovarian Cancer That Has Progressed Through PARP Inhibitor Therapy

“Drug supply issues”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 2

Sponsor

National Cancer Institute (NCI)

Sponsor type

US National Institutes of Health

Conditions

Platinum-Refractory Fallopian Tube Carcinoma; Platinum-Refractory Ovarian Carcinoma; Platinum-Refractory Primary Peritoneal Carcinoma; Recurrent Fallopian Tube Endometrioid Adenocarcinoma; Recurrent Fallopian Tube High Grade Serous Adenocarcinoma; Recurrent Ovarian Endometrioid Adenocarcinoma

Interventions

Computed Tomography; Copanlisib Hydrochloride; Magnetic Resonance Imaging; Olaparib; Paclitaxel; Pegylated Liposomal Doxorubicin Hydrochloride

Participants

0

Sites

5

Countries

United States

Trials that died the same way

• Phase II Study of Fludarabine, Cytarabine (ARA-C) and Erwinase IV in Patients With Relapsed or Refractory Hematologic Malignancies
  “Problem with drug supply” (92% match in meaning)
• Treatment of Cancer-Related Bone Pain by Using Bone-Targeted Radiation-Based Therapy (Sn-117m-DTPA) in Patients With Prostate Cancer That Has Spread to Bones
  “Insufficient drug supply” (84% match in meaning)
• EphB4-HSA Fusion Protein and Cytarabine /or Liposomal Vincristine in Patients With Recurrent or Refractory Acute Leukemia
  “Study drug supply issue” (83% match in meaning)
• rhEndostatin Protein Involving Pediatric Patients With Cancer
  “Lack of drug supply” (83% match in meaning)
• A Study of Panobinostat in Pediatric Patients With Solid Tumors Including MRT/ATRT
  “Drug supply” (83% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.